Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan long-term extension study in paroxysmal nocturnal hemoglobinuria
jRCT2031220046Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Nov 2019
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Nov 2019; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031220046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220046.